Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) had its price objective lifted by equities researchers at Royal Bank Of Canada to $166.00 in a report issued on Tuesday. Royal Bank Of Canada’s price objective points to a potential upside of 21.47% from the stock’s current price.

Several other equities research analysts have also recently issued reports on the stock. Cowen and Company reaffirmed an “outperform” rating and set a $122.00 target price on shares of Alexion Pharmaceuticals in a research note on Monday, July 3rd. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $165.00 target price on shares of Alexion Pharmaceuticals in a research note on Friday, July 14th. Leerink Swann lifted their target price on shares of Alexion Pharmaceuticals from $136.00 to $170.00 and gave the stock an “outperform” rating in a research note on Friday, July 28th. Morgan Stanley reaffirmed an “overweight” rating and set a $153.00 target price (up previously from $141.00) on shares of Alexion Pharmaceuticals in a research note on Friday, July 28th. Finally, Deutsche Bank AG reaffirmed a “buy” rating and set a $158.00 target price (up previously from $153.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Six equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $154.51.

Shares of Alexion Pharmaceuticals (ALXN) traded up 1.08% during trading on Tuesday, hitting $136.66. 4,905,786 shares of the company were exchanged. Alexion Pharmaceuticals has a 12 month low of $96.18 and a 12 month high of $149.34. The firm’s 50-day moving average price is $142.08 and its 200 day moving average price is $128.11. The firm has a market capitalization of $30.50 billion, a PE ratio of 59.26 and a beta of 1.39.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The company had revenue of $912.00 million for the quarter, compared to analysts’ expectations of $846.15 million. During the same quarter in the previous year, the company posted $1.13 EPS. The firm’s quarterly revenue was up 21.1% on a year-over-year basis. On average, equities research analysts expect that Alexion Pharmaceuticals will post $5.60 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Alexion Pharmaceuticals, Inc. (ALXN) PT Raised to $166.00 at Royal Bank Of Canada” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/24/alexion-pharmaceuticals-inc-alxn-pt-raised-to-166-00-at-royal-bank-of-canada.html.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 700 shares of the business’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the sale, the director now directly owns 6,315 shares in the company, valued at $869,828.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ann M. Veneman sold 835 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the sale, the director now owns 5,480 shares in the company, valued at $799,038.80. The disclosure for this sale can be found here. Insiders have sold 17,190 shares of company stock worth $2,433,669 over the last quarter. Insiders own 4.35% of the company’s stock.

A number of large investors have recently modified their holdings of the business. Raymond James Trust N.A. increased its stake in Alexion Pharmaceuticals by 27.2% during the third quarter. Raymond James Trust N.A. now owns 2,132 shares of the biopharmaceutical company’s stock worth $299,000 after purchasing an additional 456 shares during the period. Xact Kapitalforvaltning AB increased its stake in Alexion Pharmaceuticals by 1.3% during the third quarter. Xact Kapitalforvaltning AB now owns 42,043 shares of the biopharmaceutical company’s stock worth $5,898,000 after purchasing an additional 537 shares during the period. Handelsbanken Fonder AB increased its stake in Alexion Pharmaceuticals by 6.8% during the third quarter. Handelsbanken Fonder AB now owns 47,400 shares of the biopharmaceutical company’s stock worth $6,650,000 after purchasing an additional 3,000 shares during the period. Fox Run Management L.L.C. increased its stake in Alexion Pharmaceuticals by 137.1% during the third quarter. Fox Run Management L.L.C. now owns 8,300 shares of the biopharmaceutical company’s stock worth $1,164,000 after purchasing an additional 4,800 shares during the period. Finally, BB&T Corp increased its stake in Alexion Pharmaceuticals by 8.1% during the third quarter. BB&T Corp now owns 6,171 shares of the biopharmaceutical company’s stock worth $866,000 after purchasing an additional 463 shares during the period. Institutional investors own 94.15% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.